HomeCompareOBMCX vs JNJ

OBMCX vs JNJ: Dividend Comparison 2026

OBMCX yields 1.29% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBMCX wins by $1.5K in total portfolio value
10 years
OBMCX
OBMCX
● Live price
1.29%
Share price
$55.57
Annual div
$0.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.5K
Annual income
$140.69
Full OBMCX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — OBMCX vs JNJ

📍 OBMCX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBMCXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBMCX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBMCX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBMCX
Annual income on $10K today (after 15% tax)
$109.96/yr
After 10yr DRIP, annual income (after tax)
$119.59/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $584.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBMCX + JNJ for your $10,000?

OBMCX: 50%JNJ: 50%
100% JNJ50/50100% OBMCX
Portfolio after 10yr
$20.8K
Annual income
$484.23/yr
Blended yield
2.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OBMCX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBMCX buys
0
JNJ buys
0
No recent congressional trades found for OBMCX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBMCXJNJ
Forward yield1.29%3.36%
Annual dividend / share$0.72$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$21.5K$20.0K
Annual income after 10y$140.69$827.78
Total dividends collected$1.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OBMCX vs JNJ ($10,000, DRIP)

YearOBMCX PortfolioOBMCX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,829$129.37$10,676$355.77+$153.00OBMCX
2$11,718$130.93$11,407$389.39+$311.00OBMCX
3$12,671$132.41$12,198$426.53+$473.00OBMCX
4$13,692$133.81$13,056$467.62+$636.00OBMCX
5$14,785$135.13$13,987$513.12+$798.00OBMCX
6$15,957$136.38$14,998$563.56+$959.00OBMCX
7$17,211$137.55$16,098$619.52+$1.1KOBMCX
8$18,555$138.66$17,295$681.69+$1.3KOBMCX
9$19,993$139.71$18,599$750.82+$1.4KOBMCX
10$21,533$140.69$20,022$827.78+$1.5KOBMCX

OBMCX vs JNJ: Complete Analysis 2026

OBMCXStock

The fund invests, under normal circumstances, at least 80% of its net assets in the securities of very small companies which, at the time of purchase, have a market capitalization of less than or equal to $600 million or are within the range of companies represented in the Russell Micro-Cap Growth Index, whichever is greater. It invests principally in the common stocks of companies that the fund's investment adviser believes have the potential for significant long-term growth in market value.

Full OBMCX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this OBMCX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBMCX vs SCHDOBMCX vs JEPIOBMCX vs OOBMCX vs KOOBMCX vs MAINOBMCX vs ABBVOBMCX vs MRKOBMCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.